AVASTIN

UNIVADIS - AVASTIN /univadis/AVASTIN.md

ATC

Μορφές: C/S.SOL.IN

Ημερομηνία	barcode	code	περιεχομενο	τιμή παραγωγός	χονδρική	λιανική
05/2018	2802676901012	267690101	AVASTIN C/S.SOL.IN 100 MG/4 ML BT x 1 VIAL x 4 ML	248.21	251.93	299.09
05/2018	2802676902019	267690201	AVASTIN C/S.SOL.IN 400 MG/16 ML BT x 1 VIAL x 16 ML	923.25	937.10	1047.96

DRUGBANK - Bevacizumab
indication:
As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.
pharmacology:
mechanism:
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. This prevents blood vessel proliferation and tumour metastasis.
toxicity:
absorprion:
halflife:
roouteelimination:
volumedistribution:
clearance:
* 0.26 L/day [Male patients who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] * 0.21 L/day [Female patients who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] * 0.25 L/day [Patients with higher tumor burden who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks] * 0.2 L/day [patients with tumor burdens below the median who received 1 to 20 mg/kg of Avastin weekly, every 2 weeks, or every 3 weeks]